Kymera Therapeutics Stock Downgraded Amid Mixed Analyst Views
Wolfe Research downgraded Kymera Therapeutics to Peer Perform on January 6, removing its $92 price target, while BTIG and Citigroup maintained Buy ratings. The stock had gained over 28% in three months, with Wall Street anticipating further growth.